A multicenter prospective real-world cohort study of direct oral anticoagulant use for venous thromboembolism prophylaxis in nephrotic syndrome

BMC Nephrology 2026 Open access

Read full text
Authors: Priti Meena, Nitin Kumar, Sandip Kumar Panda, Sharon Kandari, Ganesh Srinivasa Prasad, Vinant Bhargava, Vikash Khandelia, PrashantBharat Malviya, Nikunj Kishore Rout, Paromita Das, Anish Garg, Badari Mylliemngap
+1 more Prity Rai Kumari
DOI: 10.1186/s12882-026-04836-x
Cited by: 0
References: 21

Abstract

Abstract Introduction : Patients with nephrotic syndrome (NS), particularly with severe hypoalbuminia are at significantly increased risk for venous thromboembolism (VTE). Although vitamin K antagonists (VKAs) have traditionally been used for prophylaxis. Evidence supporting direct oral anticoagulants (DOACs) for primary prophylaxis in NS remains scarce, with a lack of prospective real-world data. Methods : We conducted a prospective multicentric cohort study across eight tertiary centers in India, enrolling adults (≥ 18 years) with NS and severe hypoalbuminemia (albumin < 2.4 g/dL for Membranous nephropathy;

Fields of Study & Subjects

Venous Thromboembolism Diagnosis and Management Blood Coagulation and Thrombosis Mechanisms Renal Diseases and Glomerulopathies

Publication details

Journal / source
BMC Nephrology
Volume
27
Issue
1
Publication date
17 February 2026
Language
EN